Bausch Health Companies Inc.

Equities

BHC

CA0717341071

Pharmaceuticals

Real-time Estimate Cboe BZX 11:35:07 2024-03-28 am EDT 5-day change 1st Jan Change
10.66 USD +1.67% Intraday chart for Bausch Health Companies Inc. +12.37% +33.10%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bausch + Lomb to Present New Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Bausch + Lomb Brief: Says Will Present New Scientific Data and Analyses at American Society of Cataract and Refractive Surgery Annual Meeting MT
Toronto healthcare stocks rise in flat market, Canada Goose slides RE
Billionaires sought to help fund Trump bond in civil fraud case, sources say RE
Trump floats billionaire Paulson as potential Treasury chief, Bloomberg reports RE
Bausch Health's Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of Relistor MT
Bausch Health Brief: Salix Pharmaceuticals Announcing a Phase 2 Investigator-Initiated Study of RELISTOR (methylnaltrexone bromide: MNTX) in Patients with Resectable Head and Neck Squamous Cell Carcinoma MT
Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma CI
RBC Raises Bausch Health Target to US$9, After Q4 And 2024 Guidance MT
RBC Lifts Price Target on Bausch Health to $9 From $8, Keeps Sector Perform Rating MT
TSX closes at 22-month high powered by tech rally RE
Bausch + Lomb's Likely to Face Market-Related Risks From Spin, RBC Says MT
Toronto Stocks Climb, Loblaw Shares Rise on 4Q Profit, Revenue Growth DJ
Bausch Health's Q4 Loss Narrows, Revenue Increases; Issues 2024 Revenue Outlook; Shares Gain Pre-Bell MT
Transcript : Bausch Health Companies Inc., Q4 2023 Earnings Call, Feb 22, 2024
Bausch Health Reports Q4 2023 Adjusted Earnings of US$406 Million; Revenue of US$2.4 Billion MT
Bausch Health Companies Inc. Reports Goodwill Impairments for the Fourth Quarter Ended December 31, 2023 CI
Bausch Health Companies Inc. Provides Earnings Guidance for the Year 2024 CI
Bausch Health Brief: Adjusted EBITDA Attributable of US$869 million for the quarter, up 6%, and $3.0 billion for the year, in line with prior year MT
Bausch Health Brief: Fourth-Quarter revenues of US$2.41 billion, up 10% on a Reported basis and up 4% on an Organic Basis MT
Bausch Health Companies Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Nvidia Ignites Global Tech Shares DJ
Needham Reviews Bausch + Lomb's Q4 MT
Bausch + Lomb Offers Upbeat 2024 Revenue Outlook as Fourth-Quarter Results Exceed Views MT
Bausch + Lomb Q4 Revenue of US$1.173 Billion; GAAP Net Loss Attributable to Co of $54 Million; Provides 2024 Guidance MT
Chart Bausch Health Companies Inc.
More charts
Bausch Health Companies Inc. is a global diversified pharmaceutical company. The Company develops, manufactures, and markets a range of products primarily in gastroenterology (GI), hepatology, neurology, dermatology, eye health, and others, through Bausch + Lomb Corporation. Its Salix segment consists of sales in the United States of GI products. Its International segment consists of sales, with the exception of sales of Bausch + Lomb products and Solta Medical aesthetic medical devices, outside the United States and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical products and other products. Its Solta Medical segment consists of global sales of Solta Medical aesthetic medical devices. Its Diversified segment consists of sales in the United States of pharmaceutical products in the areas of neurology and certain other therapeutic classes. Its Bausch + Lomb segment consists of global sales of Bausch + Lomb Vision Care, surgical and pharmaceutical products.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
10.49 USD
Average target price
9.786 USD
Spread / Average Target
-6.71%
Consensus
  1. Stock
  2. Equities
  3. Stock Bausch Health Companies Inc. - Nyse
  4. News Bausch Health Companies Inc.
  5. Bausch Health Brief: Says FDA Approves Bausch + Lomb Device For Use In Ophthalmic Surgery